Table 1.

Demographics and baseline patient characteristics

Stage 1 (n = 56)Stage 2 (n = 64)All (n = 120)
Sex
 Female21 (37.5%)31 (48.4%)52 (43.3%)
Age
 Mean (SD)56.8 (10.8)59.2 (12.4)58.1 (11.7)
 Median58.058.558.0
 Minimum–maximum35–8425–8325–84
Performance status
 036 (64.3%)30 (46.9%)66 (55.0%)
 120 (35.7%)34 (53.1%)54 (45.0%)
Cancer type
 MPM6 (10.7%)27 (42.2%)33 (27.5%)
 Peritoneal mesothelioma2 (3.6%)1 (1.6%)3 (2.5%)
 Head and neck (SCCHN)0 (0%)15 (23.4%)15 (12.5%)
 Colorectal8 (14.3%)4 (6.2%)12 (10%)
 Gastrointestinal stromal tumor10 (17.9%)1 (1.6%)11 (9.2%)
 Sarcoma8 (14.3%)3 (4.7%)11 (9.2%)
 Breast3 (5.4%)6 (9.4%)9 (7.5%)
 Non–small cell lung1 (1.8%)3 (4.7%)4 (3.3%)
 Ovarian2 (3.6%)1 (1.6%)3 (2.5%)
 Esophageal1 (1.8%)1 (1.6%)2 (1.7%)
 Other15 (26.8%)2 (3.1%)17 (14.1%)
Number of prior systemic therapies
 Mean (SD)3.7 (2.8)2.8 (2.0)3.2 (2.4)
 Median3.02.03.0
 Range0–130–100–13
Months from primary diagnosis
 Mean (SD)55.4 (42.3)37.6 (34.9)45.9 (39.4)
 Median42.224.231.9
 Range6–2105–1565–210